Table 1.
Experiment 1.A: Single-Exposure CPFE Preexposure day Egr-1 expression PD17 and PD24 | |||||||||
---|---|---|---|---|---|---|---|---|---|
| |||||||||
AC | PL | IL | |||||||
n (HC, Alt-Pre, Pre) | n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | |||||||
|
|||||||||
PD17 | 13, 11, 12 | 13, 11, 11 | 13, 12, 12 | ||||||
PD24 | 12, 10**, 11 | 12, 10**, 13* | 12, 10***, 12** | ||||||
F | p | F | p | F | p | ||||
|
|||||||||
Age | 14.36 | <. .001 | PD24>PD17 | 15.63 | <.001 | PD24 >PD17 | 14.63 | <.001 | PD24 > PD17 |
|
|||||||||
Preexposure | 4.15 | 0.02 | Alt-Pre > HC | 4.92 | 0.01 | Pre, Alt-Pre > HC | 16.66 | <.001 | Pre, Alt-Pre > HC |
|
|||||||||
Age x Preexposure | 3.88 | 0.03 | PD 24 Pre, Alt-Pre > PD 17, HC | 4.18 | 0.02 | PD 24 Pre, Alt-Pre > PD 17, HC | 4.04 | 0.02 | PD 24 Pre, Alt-Pre > PD 17, HC |
|
|||||||||
OFC | dHPC | dLA | |||||||
n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | n (HC, Alt-Pre, Pre) | |||||||
|
|||||||||
PD17 | 13, 12, 11 | 11, 12, 12 | 12, 12, 12 | ||||||
PD24 | 11, 11***, 12** | 12, 10, 11** | 12, 11***, 10*** | ||||||
F | p | F | p | F | p | ||||
|
|||||||||
Age | 15.57 | <.001 | PD24>PD17 | 8.04 | <01 | PD24>PD17 | 20.6 | <.001 | PD24>PD17 |
|
|||||||||
Preexposure | 8.74 | .<001 | Pre, Alt-Pre> HC | 4.84 | 0.01 | Pre, Alt-Pre > HC | 8.27 | <.001 | Pre, Alt-Pre > HC |
|
|||||||||
Age x Preexposure | 4.89 | 0.01 | PD24 Pre, Alt-Pre > PD 17, HC | 3.14 | 0.0502 | NS | 6.03 | <.01 | PD 21 Pre, Alt-Pre > PD 17, HC |
| |||||||||
Experiment 1B: Single-Exposure CPFE Training day Egr-1 expression PD17 and PD24 | |||||||||
| |||||||||
AC | PL | IL | |||||||
n (HC, Alt-Pre, Pre) | n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | |||||||
|
|||||||||
PDI7 | 13, 12**, 11** | 13, 12***, 11*** | 13, 12***, 11** | ||||||
PD24 | 12, 12**, 10** | 12, 10***, 11** | 12, 10***, 11*** | ||||||
F | p | F | p | F | p | ||||
|
|||||||||
Age | 0.18 | 0.68 | NS | 0.55 | 0.46 | NS | 9.39 | <.01 | PD24 > PD27 |
|
|||||||||
Preexposure | 6.24 | <.01 | Pre, Alt-Pre > HC | 20.94 | <.001 | Pre. Alt-Pre > HC | 16.12 | <.001 | Pre, Alt-Pre > HC |
|
|||||||||
Age x Preexposure | 0.23 | 0.8 | NS | 1.54 | 0.22 | NS | 2.46 | 0.09 | NS |
|
|||||||||
OFC | dHPC | dLA | |||||||
n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | n (HC Alt-Pre, Pre) | |||||||
|
|||||||||
PD17 | 13, 13***, 11** | 12, 12***, 9* | 12, 10***, 11*** | ||||||
PD24 | 12, 10***, 11** | 12, 10***, 11* | 12, 11**, 12 | ||||||
F | P | F | p | F | p | ||||
|
|||||||||
Age | 0.47 | 0.49 | NS | 1.54 | 0.22 | NS | 0.99 | 0.32 | NS |
|
|||||||||
Preexposure | 11.50 | <.001 | Pre, Alt-Pre > HC | 15.72 | <.001 | Alt-Pre > Pre > HC | 13.37 | <.001 | Alt-Pre > Pre > HC |
|
|||||||||
Age x Preexposure | 0.15 | 0.86 | NS | 0.45 | 0.64 | NS | 1.52 | 0.23 | NS |
| |||||||||
Experiment 1C: Single-Exposure CPFE Training day Egr-1 expression PD31 | |||||||||
| |||||||||
AC | PL | IL | |||||||
n (HC, Alt-Pre, Pre) | n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | |||||||
|
|||||||||
PD31 | 12, 12**, 11** | 12, 12*, 12*** | 12, 12**, 12*** | ||||||
F | p | F | p | F | p | ||||
|
|||||||||
Preexposure | 7.08 | < .01 | Pre, Alt-Pre > HC | 12.02 | <.001 | Pre > Alt-Pre >HC | 13.32 | < .001 | Pre > Alt-Pre >HC |
|
|||||||||
OFC | dHPC | dLA | |||||||
n (HC, Alt-Pre, Pre) | n (HC, Pre, Alt-Pre) | n (HC, Pre, Alt-Pre) | |||||||
|
|||||||||
PD31 | 12, 12*, 12* | 11, 12, 12 | 11, 12, 12 | ||||||
F | p | F | p | F | p | ||||
|
|||||||||
Preexposure | 3.80 | 0.03 | Pre, Alt-Pre > HC | 2.87 | 0.069 | 3.04 | 0.059 |
Asterisks (next to group n) represent Newman-Keuls post hoc tests comparing experimental groups to homecage (HC) controls.
p < .05,
p < .01,
p < .001.
Main or interaction effects are described by inequality signs (> or <) and non-significant effects are listed as “NS.”